Dihydropteridine reductase deficiency: Levodopa's long-term effectiveness without dyskinesia

Neurology

Volumn 67, Issue 12, 2006, Pages 2243-2245

  Sedel, F ^a   Ribeiro, M J ^b   Remy, P ^c,d   Blau, N ^f   Saudubray, J M ^e   Agid, Y ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^c DIF   (France)

^d FACULTÉ DE MÉDECINE   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; BENSERAZIDE PLUS LEVODOPA; CATECHOLAMINE; DOPAMINE; DOPAMINE TRANSPORTER; FOLINIC ACID; LEVODOPA; SEROTONIN;

ADULT; ARTICLE; CASE REPORT; CATECHOLAMINE METABOLISM; CELL LOSS; DEPRESSION; DIHYDROPTERIDINE REDUCTASE DEFICIENCY; DOPAMINE METABOLISM; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; DYSKINESIA; ENZYME DEFICIENCY; FOLIC ACID DEFICIENCY; HUMAN; LONG TERM CARE; MALE; MENTAL DEFICIENCY; MONOAMINE METABOLISM; NEUROIMAGING; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEROTONIN METABOLISM; SIDE EFFECT;

5-HYDROXYTRYPTOPHAN; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DOPAMINE AGENTS; DRUG COMBINATIONS; DYSKINESIA, DRUG-INDUCED; DYSKINESIAS; HUMANS; LEVODOPA; LONGITUDINAL STUDIES; MALE; PHENYLKETONURIAS; TREATMENT OUTCOME;

EID: 33845923820     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000249335.35585.3e     Document Type: Article

References (10)

1. Blau N, Thony B, Cotton R, Hyland K. Disorders of tetrahydrobiopterin and related biogenic amines. Scriver CR, Sly WR, Childs B, eds. The metabolic and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill Professional, 2001:1725-1776.
2. Rey F, Harpey JP, Leeming RJ, et al. Hyperphenylalaninaemia with normal phenylalanine-hydroxylase activity and a deficiency of tetrahydrobiopterin and dihydropteridine reductase. Arch Fr Pediatr 1977;34:59-60.
3. Santiago-Ribeiro MJ, Lohmann E, Brice A, et al. Striatal dopaminergic metabolism and dat density in young onset Parkinson's disease patients: a PET study with [18F]fluoro-L-dopa and [11C]PE2I. Int J Nucl Med 2005;46(suppl 2):296-P.
4. Blau N, Sperl W, Hoffman GF, et al. Atypical (mild) forms of dihydropteridine reductase deficiency: neurochemical evaluation and mutation detection. Pediatr Res 1992;32:726-730.
5. Linazaroso G. New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol Sci 2005;26:391-397.
6. Kunig G, Leenders KL, Antonini A, et al. D2 receptor binding in dopa-responsive dystonia. Ann Neurol 1998;44:758-762.
7. Agid Y. Levodopa. Is toxicity a myth? Neurology 2001;7(suppl 3):S46-S51.
8. Quinn NP, Parkes D, Janota I, et al. Case report: preservation of the substantia nigra and the locus coeruleus in a patient receiving levodopa plus decarboxylase inhibitor over a four year period. Mov Disord 1986;1:65-68.
9. Dudesek A, Roschinger W, Muntau AC, et al. Molecular analysis and long-term follow-up of patients with different forms of 6- pyruvoyltetrahydropterin synthase deficiency. Eur J Pediatr 2001;160:267-276.
10. Roze E, Vidailhet M, Blau N, et al. Long-term follow-up and adult outcome of 6-pyruvoyl-tetrahydropterin synthase deficiency. Mov Disord 2006;21:263-6.